Phase 2 Colorectal Cancer Trial, Recruiting NCT06242418 Sponsor: West China Hospital Condition: Colorectal Cancer
Back to Colorectal Cancer

Phase 2 Colorectal Cancer Trial, Recruiting

NCT06242418
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People between 18 and 75 years of age, of any gender
  • People whose tumor is located in the colon, where the bottom edge of the tumor is more than 12 cm away from the anus
  • People who have already had surgery to remove the tumor, and whose cancer was confirmed by laboratory testing to be at stage III (meaning it spread to nearby lymph nodes but not to other parts of the body)
  • People whose recent scans show no signs of the cancer coming back or spreading
  • People who are generally well enough to carry out light activity and care for themselves (a fitness level rated 0 or 1 on a standard medical scale)
  • People whose blood counts, kidney function, and liver function meet the minimum levels required by the trial (confirm specific values with the trial site)
  • People with no history of allergic reactions to a class of chemotherapy drugs called fluoropyrimidines or platinum-based drugs
  • People who are willing to participate, sign a consent form, and attend follow-up appointments as required

Who may not be able to join:

  • People who have had another type of cancer in the past five years, with the exception of certain skin cancers or early-stage cervical cancer that was treated with curative surgery
  • People whose tumor has a specific gene change known as a BRAF mutation
  • People whose tumor has features called microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) — these are characteristics identified through laboratory testing of the tumor tissue (confirm with trial site)
  • People who have already received chemotherapy, radiation, targeted therapy, or immunotherapy for their colon cancer
  • People who may have a hereditary condition called Lynch syndrome
  • People with serious heart, blood vessel, brain, liver, kidney, or blood disorders
  • People with severe mental health conditions
  • People whose current situation may make it unsafe or difficult to participate, including those with a current need or plan to become pregnant, people who are pregnant or breastfeeding, or people with conditions such as depression, bipolar disorder, obsessive-compulsive disorder, or schizophrenia
  • People who are currently taking part in, or have recently taken part in, another clinical drug trial
  • People considered unsuitable for the trial by the treating doctor, for any reason

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +8685422480

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
West China Hospital
Registry
ClinicalTrials.gov
Start date
25 March 2024
Est. completion
31 December 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

change in value of ctDNA concentration

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov